Volume 5, Issue 2, June 2019, Page: 56-63
Drug-Induced Liver Diseases in Children and Adolescents
Sergey Postnikov, Chair of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation
Nataliya Teplova, Chair of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation
Aleksey Ermilin, Chair of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation
Anna Gratzhianskaya, Chair of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation
Marya Kostyleva, Chair of Clinical Pharmacology, Russian National Research Medical University Named After Pirogov, Moscow, Russian Federation
Received: Mar. 9, 2019;       Accepted: Apr. 22, 2019;       Published: May 20, 2019
DOI: 10.11648/j.ajp.20190502.14      View  111      Downloads  44
Abstract
Many drugs (now it’s known more than 1200) are associated with hepatic side effects. Children (especially newborns and infants) are unique population with specific characteristics of absorption, metabolism and elimination of drugs that can predispose to hepatotoxicity. Aim of this review is to estimate risk factors of hepatotoxicity related to the patients’ peculiarities and drug itself, also to describe some mechanisms and types of drug-induced liver disease (DILD) and beside this to offer some methods of the treatment and prevention of hepatotoxicity. In children the most often mentioned drugs caused DILD are antibiotics, psychotropics and NSAIDs and the main type of DILD is acute hepatitis with mortality of 10%. To conclude it’s highly important to monitor activity of hepatic enzymes (ALT, AST, AP) during treatment by potentially hepatotoxic drugs in patients from risk groups (early age, any liver disease, diabetes mellitus, obesity, poor nutritional status) in order to timely withdraw offending drug and prescribe hepatoprotectors or even perform liver transplantation.
Keywords
Drug and Liver Disease, Risk Factors of Hepatotoxicity, Mechanisms and Types of DILD, Hepatoprotectors, Prevention of DILD
To cite this article
Sergey Postnikov, Nataliya Teplova, Aleksey Ermilin, Anna Gratzhianskaya, Marya Kostyleva, Drug-Induced Liver Diseases in Children and Adolescents, American Journal of Pediatrics. Vol. 5, No. 2, 2019, pp. 56-63. doi: 10.11648/j.ajp.20190502.14
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Polyansky V. M. Use of LIV-52 in toxic, alcohol-induced and drug-induced liver injuries. Pharmateka, 2005, 7 (102), pp 23-28.
[2]
Daniele Serranti, Carlotta Montagnani, Giuseppe Indolfi, Elena Chiappini, Luisa Galli & Maurizio de Martino (2013) Antibiotic induced liver injury: what about children?, Journal of Chemotherapy, 25: 5, 255-272.
[3]
Shi Q, Yang X, Greenhaw JJ, Salminen AT, Russotti GM, Salminen WF. Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status. Int J Toxicol. 2017 Sep/Oct; 36 (5): 365-379.
[4]
Ferrajolo, C., Verhamme, K. M. C., Trifirò, G. et al. Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases. Drug Saf (2017) 40: 305.
[5]
Molleston JP, Fontana RJ, Lopez MJ, et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr. 2011; 53 (2): 182-9.
[6]
Lewis, J. H., & Stine, J. (2013). Nonsteroidal antiinflammatory drugs and leukotriene receptor antagonists. InDrug-Induced Liver Disease (pp. 369-401). Elsevier Inc.
[7]
Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003; 327 (7405): 18-22.
[8]
Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. Int J Hepatol. 2018; 2018: 5253623. Published 2018 Jan 15.
[9]
MacLaren. Hepatic and cholestatic disease. Drug-induced disease. Prevention. Detection and management. American Society of Health System, Pharmacist, Bethesta, 2010, сhapter 40, p. 771–800.
[10]
Evseev M. A. Hepatic and gastric toxicity of non-steroid anti-inflammatory drugs, possible cross-over points. http://rmj.ru/articles5705.htm. 20. 06. 2011.
[11]
Shulpekova Y. O. Drug-induced liver diseases. http://dd.consilium-medicum.com/medialgastro107_01/16.shtm от 20. 06. 2011.
[12]
Ushkalova E. A. Drug-induced liver diseases. Collected articles. M. Transatlantic international, 2003, pp. 10-25.
[13]
Yakovenko E. P., Agafonova N. A., Yakovenko A. V., Ivanov A. N., Kovtun A. V. Pathogenetic approach to the choice of hepatic protectors during treatment of drug-induced liver diseases. Lechebnoye delo, 2017, #2.
[14]
Pylaeva O. A., Mukhin K. Y., Petrukhin A. S. “Adverse effects of anticonvulsants” (M.: GRANAT, 2016. 232).
[15]
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003 Sep 18; 349 (12): 1157-67.
[16]
Amin MD, Harpavat S, Leung DH. Drug-induced liver injury in children. Curr Opin Pediatr. 2015 Oct; 27 (5): 625-33.
[17]
Mikheeva O. M., Komissarenko I. A., Akopova A. O., Ivkina T. I. Drug metabolism in patients with liver pathology. Therapy, 2015, #2.
[18]
Kukes V. G., Volodin N. N., Sychev D. A., Koman I. E. “Specifics of drugs use in children”. Vestnik of pediatric pharmacology and nutriciology. 2006, v. 1, #1, pp. 16-23.
[19]
Zyryanov S. K., Sokolov A. V., Belousov Y. B. (2011). Pharmacokinetics of drugs in children of different age groups. Medical technologies. Assessment and selection, (2), 70-76.
[20]
Vo HD, Xu J, Rabinowitz SS, Fisher SE, Schwarz SM. The liver in pediatric gastrointestinal disease. J Pediatr Gastroenterol Nutr. 2014 Sep; 59 (3): 288-99.
[21]
Schwab M, Seyringer E. at al. Fatal MDMA intoxication. The Lancet vol 353, № 9152, 1999: 593-594.
[22]
Karlovitz N. Drug induced liver injury. Drug safety. 2007; 30 (4): 277–294.
[23]
Alyeva A. A., Nikitin I. G., Arkhipov A. V. Concomitant treatment of acute drug-induced liver injury caused by chemotherapy in patients with breast cancer. // Lechebnoe delo. 2018. №2.
[24]
Zborovsky A. B., Belousov Y. B. Adverse drug reactions of drugs. Medical inform. agency, 2008. 651.
[25]
Andrade RJ, Lucena NJ, Kaplowitz, et al. Outcome of idiosyncratic drug-induced liver injury: long-term follow up in a hepatotoxity registry. Hepatology. 2006; 44 (issue 6): 1581–1588.
[26]
Bagneri H, Michel F, Lapeyre-Mestre M, et al. Detection and incidence of drug induced liver injuries in hospital: a prospective analysis from laboratory signals. British Journal of Clinical Pharmacology. 2000; 50 (issue 5): 479–484.
[27]
Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997; 26 (3): 664–669.
[28]
Deogaonkar Viplav Narayan, Shah Ira. Drug-induced liver injury in children – Case series from Mumbai. Medical Journal of Dr. D. Y. Patil Vidyapeeth. 2018; 11 (issue 6): 542-544.
[29]
Vas MB, Abrams SH, Barlow SE, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017; 64 (2): 319-334.
[30]
Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug induced liver injury: a population based case-control study. British Journal of Clinical Pharmacology. 2004; 58 (1): 71–80.
[31]
Kamalova A. A., Shakirova A. R., Skvortzova I. V., Bikmullina G. M. Opportunities of ultrasound Doppler in diagnostics and assessment of treatment effectiveness for chronic liver diseases in children. XVIII Congress of children gastroenterologists in Russia and CIS. “Actual problems of abdominal pathology in children”. M., 2011: 234–235.
[32]
Romanova S. V., Zhukova E. A., Kaplina N. A. and al. Changes of serum parameters in case of liver fibrosis in children. XVIII Congress of children gastroenterologists in Russia and CIS. “Actual problems of abdominal pathology in children”. M., 2011. 240–241.
[33]
Pykov M. I., Zakharova I. N., Kaloeva Z. V. and al. Ultrasound diagnostics of hepatomegaly in children. XVIII Congress of children gastroenterologists in Russia and CIS. “Actual problems of abdominal pathology in children”. M., 2011. 231–232.
[34]
Watkins PB, Duba LM, Walton-Bowen K, et al. Clinical pattern of zilenton associated liver injury. Drug safety. 2007; 30 (9): 805–815.
[35]
Polunina T. E. Personalized approaches to selection of drug for treatment of liver diseases. Lectures for practicing physicians. Materials of 22 Russian National congress “Man and drug”, 2016: 189-190.
[36]
Singh D, Cho WC and Upadhyay G (2016) Drug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An Overview. Front. Physiol. 6: 363.
[37]
Gundermann, Karl-Josef et al. “Essential phospholipids in fatty liver: a scientific update” Clinical and experimental gastroenterology vol. 9 105-17. 5 May. 2016.
[38]
Borzakova S. N., Reyzis A. R. Principles of diagnosis and therapy of drug-induced liver injury in children with tuberculosis. Ros Vestn Perinatol i Pediatr 2018; 63: (3): 91–97 (in Russ).
[39]
Zakharova I. N., Pykov M. I., Mumladze E. B. and al. Functional condition of liver in patients receiving hepatic protective treatment. XVIII Congress of children gastroenterologists in Russia and CIS. “Actual problems of abdominal pathology in children”. M., 2011 232–233.
Browse journals by subject